Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar

Paul Schloesser

Associate Editor

Coherus BioSciences is adding to its pipeline, this time grabbing commercialization rights for a biosimilar of one of the largest ophthalmology drugs on the market …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Co­herus pays out $32M for ex­clu­sive US com­mer­cial­iza­tion rights to Eylea biosim­i­lar

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar